User:Mr. Ibrahem/Tildrakizumab

Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody used to treat plaque psoriasis. In the United Kingdom use is only recommended in severe disease that has not responded to other treatments. It is given by injection under the skin.

Common side effects include back pain, headache, infection, and nausea. Other side effects include angioedema and pain at the site of injection. Use in the months before and during pregnancy is not recommended. It works by blocking interleukin-23 (IL-23), a cytokine.

Tildrakizumab was approved for medical use in the United States and Europe in 2018. In the United Kingdom it costs the NHS about £3,250 per dose as of 2021. This amount in the United States costs about 15,300 USD.